⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11325372 | 0.67 | — | — | |
| SCHEMBL15545588 | 0.65 | — | — | |
| SCHEMBL6970728 | 0.65 | — | — | |
| SCHEMBL11985923 | 0.65 | — | — | |
| SCHEMBL8917147 | 0.65 | — | — | |
| SCHEMBL13912859 | 0.65 | — | — | |
| SCHEMBL1030891 | 0.65 | — | — | |
| SCHEMBL7055300 | 0.65 | — | — | |
| SCHEMBL5598962 | 0.65 | — | — | |
| SCHEMBL4373865 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| EP-1905762-A1 | PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-04-02 | — | — | EP | claimed |
| EP-1900728-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-03-19 | — | — | EP | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | disclosed |
| US-20100004298-A1 | P-38 INHIBITORS | DONG QING | 2010-01-07 | — | — | US | disclosed |
| EP-1635824-B1 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| WO-2009050227-A1 | PYRIDAZINE DERIVATIVES FOR INHIBITING BETA AMYLOID PEPTIDE PRODUCTION | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| EP-1905762-A1 | PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-04-02 | — | — | EP | disclosed |
| EP-1900728-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZOLONE DERIVATIVE | Genecare Research Institute Co., Ltd (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1635824-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | Novartis AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | disclosed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |